Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma
Authors:
- Yawen DongYDYawen Dong
- Zhihao LiZLZhihao Li
- Vanja PodrascaninVPVanja Podrascanin
- John E. EatonJEJohn E. Eaton
- Sumera I. IlyasSISumera I. Ilyas
- Gregory J. GoresGGGregory J. Gores
- Susanne G. WarnerSWSusanne G. Warner
- Tayyab S. DiwanTDTayyab S. Diwan
- David M. NagorneyDNDavid M. Nagorney
- Julie K. HeimbachJHJulie K. Heimbach
- Rory L. SmootRSRory L. Smoot
- Timucin TanerTTTimucin Taner
Open Access
- 4 July 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (5) , 1128-1142
Abstract
Background and Aims: The optimal treatment strategy for de novo perihilar cholangiocarcinoma (pCCA) remains debated. This study compares outcomes between liver transplantation following neoadjuvant chemoradiation (RT+LT) and liver resection (LR), with (LR+VR) and without vascular resection (LR w/o VR). Approach and Results: This single-center, retrospective study included patients with de novo perihilar cholangiocarcinoma treated at the Mayo Clinic Rochester (1993–2023) with curative-intent surgery. Patients underwent either (1) LR, classified as LR+VR or LR w/o VR, or (2) RT+LT following the transplant protocol. Overall survival (OS) and recurrence-free survival were analyzed using as-treated and intention-to-treat approaches, incorporating competing risk analysis and direct matching. In the as-treated analysis, RT+LT showed superior median OS compared with LR w/o VR (78.0 vs. 58.2 mo, p =0.03) and LR+VR (25.8 mo, p p =0.19). In matched as-treated analysis, RT + LT had no significant survival benefit over LR w/o VR (50.6 vs. 140.6 mo, p =0.08) or LR+VR (25.8 mo, p =0.11). Perioperative mortality was 4% (RT+LT), 7% (LR w/o VR), and 8% (LR + VR). Conclusions: Both LR and RT+LT achieve excellent oncological outcomes in selected patients with de novo perihilar cholangiocarcinoma. Key challenges remain dropouts during neoadjuvant therapy in patients planned for LT and high perioperative mortality for patients undergoing LR. OS doubles in patients undergoing LR+VR compared with dropouts, supporting LR+VR as a viable option for patients who are ineligible for LT. Appropriate patient selection is crucial, as those not undergoing surgery suffer from a dismal prognosis.Keywords
This publication has 38 references indexed in Scilit:
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The Tokyo 2020 terminology of liver anatomy and resections: Updates of the Brisbane 2000 systemJournal of Hepato-Biliary-Pancreatic Sciences, 2021
- Liver Transplantation for Peri-hilar CholangiocarcinomaJournal of Gastrointestinal Surgery, 2020
- Surgical Outcomes for Perihilar Cholangiocarcinoma with Vascular InvasionJournal of Gastrointestinal Surgery, 2018
- Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in CanadaJournal of Surgical Oncology, 2018
- Surgical resection for Bismuth type IV perihilar cholangiocarcinomaBritish Journal of Surgery, 2017
- Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinomaLiver Transplantation, 2013
- Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topicsJournal of Gastroenterology, 2012
- Improvement in Perioperative and Long-term Outcome After Surgical Treatment of Hilar CholangiocarcinomaArchives of Surgery, 2012
- Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasiaLiver Transplantation, 2006